Improving Efficiencies in Oncology Biomarker TestingVideo Categories: PMO Interview with the Innovator Series: Volume 12 and Video Library
Drs. Roy Herbst and David Rimm discuss ways in which the time required to complete biomarker testing can be reduced, from obtaining and processing tissues, performing the testing, evaluating results, and reporting results to the cancer care team.
Alexander Bastian speaks about the need for a sustainable model of pricing as related to cancer treatments and drug development. He talks about indication-based pricing or tumor-based pricing—says that is compelling, but not necessarily possible in the US.
Dr. Mesa describes why patients with PV who have a broad and heterogeneous course should seek a referral from a specialty center.Supported through funding from Incyte